- Home
- AVIR vs EDD Comparison
AVIR vs EDD Comparison
Compare AVIR & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVIR | EDD |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.3M | 371.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | AVIR | EDD |
|---|---|---|
| Price | $5.47 | $5.87 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 286.5K | ★ 311.8K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.52% |
| EPS Growth | ★ 3.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $351,367,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.78 | $4.96 |
| 52 Week High | $6.45 | $6.18 |
Technical Indicators
Market Signals| Indicator | AVIR | EDD |
|---|---|---|
| Relative Strength Index (RSI) | 65.57 | 51.63 |
| Support Level | $5.13 | $5.74 |
| Resistance Level | $5.83 | $6.03 |
| Average True Range (ATR) | 0.25 | 0.08 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 92.78 | 59.26 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.